{"id":"NCT03939312","sponsor":"Allergan","briefTitle":"Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine","officialTitle":"A Phase 3, Multicenter, Open-Label 40-week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-05-06","primaryCompletion":"2021-03-31","completion":"2021-03-31","firstPosted":"2019-05-06","resultsPosted":"2022-05-12","lastUpdate":"2022-05-12"},"enrollment":685,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Episodic Migraine"],"interventions":[{"type":"DRUG","name":"Atogepant","otherNames":[]}],"arms":[{"label":"Atogepant 60 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and tolerability of atogepant 60 mg once a day for the prevention of migraine in participants with episodic migraine.","primaryOutcome":{"measure":"Percentage of Participants With at Least 1 Treatment-Emergent Adverse Event and Treatment-Emergent Serious Adverse Event (TEAEs/TESAEs)","timeFrame":"From dose of study drug until 30 days following last dose of study drug (up to approximately Week 44)","effectByArm":[{"arm":"Atogepant 60 mg","deltaMin":62.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":113,"countries":["United States"]},"refs":{"pmids":["39648629","38462625","33942560","33142014"],"seeAlso":["http://rxabbvie.com"]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":685},"commonTop":["Upper respiratory tract infection","Urinary tract infection"]}}